FDA Clears Wireless Integration of J&J Glucometer and WellDoc Diabetes Management Platform

LifeScan Inc., part of the Johnson & Johnson Diabetes Care Companies and a leader in blood glucose monitoring, announced the U.S. Food and Drug Administration (FDA) has cleared the wireless integration of the OneTouch Verio Flex blood glucose monitoring system with WellDoc Inc.’s clinically validated diabetes management platform, BlueStar, creating a unique digital health solution for people living with Type 2 diabetes.
 
Using blood glucose data wirelessly and automatically transmitted from the OneTouch Verio Flex blood glucose monitoring system with built-in Bluetooth^[i] Smart Technology, WellDoc Inc.’s patented clinical and behavioral engine will provide patients with individualized real-time feedback and virtual coaching based on the patient’s specific treatment plan, and also help health care teams make timely diabetes management decisions. Along with the OneTouch Reveal web and mobile app, the offering seeks to create a comprehensive, data-driven and payer-reimbursed program for the management of Type 2 diabetes.
 
“Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience. Integrating digital solutions such as OneTouch Reveal mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers.” said Valerie Asbury, world wide president of LifeScan.
 
LifeScan’s OneTouch Verio Flex meter with BlueTooth Smart Technology features ColorSure technology, and is a simple, accurate and easy-to-use meter that takes the guesswork out of blood sugar test results for people with diabetes. The OneTouch Verio Flex meter also has optional wireless connectivity with the OneTouch Reveal mobile app to help patients manage their diabetes. WellDoc’s BlueStar is a digital therapeutic platform cleared by the FDA for adults with Type 2 diabetes.
 
LifeScan and WellDoc are currently working with health plans to help provide patient access for this integrated system.
 
Johnson & Johnson Diabetes Care Companies are a collaboration of Johnson & Johnson companies dedicated to diabetes and includes LifeScan, a leader in blood glucose monitoring; Animas Corporation, maker of innovative insulin delivery systems; Calibra Medical Inc. developer of OneTouch Via on-demand insulin delivery; and the Johnson & Johnson Diabetes Institute LLC, a global initiative to improve care and better outcomes worldwide through education and training programs. Globally, more than 15 million people depend on OneTouch brand products to help them manage their diabetes.

References:
[i] The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG Inc., and any use of such marks by LifeScan Scotland Ltd. is under license. Other trademarks and trade names are those of their respective owners.